The effects of clinically used MRI contrast agents on the biological properties of human mesenchymal stem cells
The effects of clinically used MRI contrast agents on the biological properties of human mesenchymal stem cells
复制标题
DOI：
10.1002/nbm.1487
复制
发表时间：
2010-06-01
影响因子：
2.9
通讯作者：
Moon, Woo Kyung
中科院分区：
文献类型：
--
作者：
Kim, Hoe Suk;Oh, Sue Young;Moon, Woo Kyung
本研究旨在比较三种铁氧化物MRI造影剂[Feridex、Resovist和单晶氧化铁（MION）]的标记效率，并评价它们对人骨髓间充质干细胞（hMSCs）生物学特性的影响。在存在聚-L-赖氨酸（0.75 μ g/mL）的情况下，用氧化铁纳米颗粒（12.5 μ g Fe/mL）标记24小时后，将hMSC培养1天和7天。与MION相比，使用Feridex、Resovist更有效地标记hMSC。标记的hMSCs的活力和增殖没有观察到显著差异。Oct-4 mRNA水平在第1天增加，细胞表型在第7天由CD 45-/CD 44 +/CD 29+变为CD 45 low/CD 44 +/CD 29+，与新鲜骨髓来源的hMSCs表型非常相似。我们的研究表明，菲立磁或Resovist是hMSCs的首选标记剂。标记后Oct-4和CD 45表达发生变化。版权所有（C）2010约翰威利父子有限公司
This study was undertaken to compare the labeling efficiencies of three iron-oxide based MRI contrast agents [Feridex, Resovist and monocrystalline iron oxide (MION)] and to evaluate their effects on the biological properties of human mesenchymal stem cells (hMSCs). The hMSCs were cultivated for 1 and 7 days after 24-h labeling with iron oxide nanoparticles (12.5 mu g Fe/mL) in the presence of poly-L-lysine (0.75 mu g/mL). The hMSCs were labeled more efficiently with use of Feridex, Resovist as compared to MION. No significant differences were observed in terms of viability and proliferation of labeled hMSCs. The level of Oct-4 mRNA increased in labeled hMSCs at day 1 and the cellular phenotype changed from CD45-/CD44+/CD29+ to CD45low/CD44+/CD29+ at day 7, which closely resembles the phenotype of fresh bone marrow-derived hMSCs. Our study has demonstrated that the Feridex or Resovist is the preferred labeling agent for hMSCs. There was a change in Oct-4 and CD45 expression after labeling. Copyright (C) 2010 John Wiley & Sons, Ltd.